MSB Trading - 2019, page-1735

Over the six-month observation period, treatment with MPC-150-IM was associated with the followingresults:• the primary endpoint of temporary weaning from full LVAD support was not achieved overall;limitation was that the high rate of pump thrombosis reduced the number of evaluable weanattempts• significant beneficial effect was observed on the primary endpoint of temporary weaning fromfull LVAD support in a pre-determined subgroup analysis of ischemic heart failure patients,representing 44% of the total trial population (rate ratio 1.55, p value for interaction =0.02)• significant reduction in cumulative incidence of major GI bleeding events by 48%, from 33%in controls to 17% (p=0.02)• significant reduction in rate of major GI bleeding events by 76%, from 15.9/100 patientmonths to 3.8/100 patient months (p<0.001)• significant reduction in rate of hospitalization for GI bleeding, a major cause of hospitalreadmissions, by 65%, from 0.21/100 patient months to 0.07/100 patient months (p=0.03);no significant reduction in all cause readmissions• no patients experienced a safety-stopping event for the trial• overall mortality was similar between the two groups, 14% vs 15% at 12 months• overall time to transplant was similar between the two groups, despite a non-significantincrease in anti-HLA class I antibodies in the MPC group (26% vs 9% in controls)

Worst case scenario - significant reduction in readmittance to hospital must be a no brainer for people close to end of life